High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy

N. T. Ueno, S. Konoplev, T. A. Buchholz, T. Smith, G. Rondón, P. Anderlini, S. A. Giralt, J. L. Gajewski, M. L. Donato, M. Cristofanilli, R. E. Champlin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. Their disease had been refractory (defined as less than partial response) to one (18 patients) or two (24 patients) regimens of neoadjuvant chemotherapy. Twenty-nine patients had surgery before HDCT. The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. Thirty patients had complete remission, eight had a PR, one had a minor response, and three had progressive disease. In seven of 13 patients whose disease was inoperable before HDCT, it became operable. After a median follow-up of 42 months, 21 patients were alive, and 15 remained disease free. Five-year overall survival (OS) was 57% (CI, 50-64%), and the estimated 5-year progression-free survival was 40% (CI, 32-48%). Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable. A randomized study is warranted in this patient population.

Original languageEnglish (US)
Pages (from-to)929-935
Number of pages7
JournalBone Marrow Transplantation
Volume37
Issue number10
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Breast Neoplasms
Drug Therapy
Thiotepa
Carmustine
Survival
Cyclophosphamide
Disease-Free Survival
Radiotherapy
Transplantation
Transplants

Keywords

  • Autologous transplantation
  • Breast neoplasm
  • High-dose chemotherapy
  • Preoperative chemotherapy
  • Resistant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. / Ueno, N. T.; Konoplev, S.; Buchholz, T. A.; Smith, T.; Rondón, G.; Anderlini, P.; Giralt, S. A.; Gajewski, J. L.; Donato, M. L.; Cristofanilli, M.; Champlin, R. E.

In: Bone Marrow Transplantation, Vol. 37, No. 10, 05.2006, p. 929-935.

Research output: Contribution to journalArticle

Ueno, NT, Konoplev, S, Buchholz, TA, Smith, T, Rondón, G, Anderlini, P, Giralt, SA, Gajewski, JL, Donato, ML, Cristofanilli, M & Champlin, RE 2006, 'High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy', Bone Marrow Transplantation, vol. 37, no. 10, pp. 929-935. https://doi.org/10.1038/sj.bmt.1705355
Ueno, N. T. ; Konoplev, S. ; Buchholz, T. A. ; Smith, T. ; Rondón, G. ; Anderlini, P. ; Giralt, S. A. ; Gajewski, J. L. ; Donato, M. L. ; Cristofanilli, M. ; Champlin, R. E. / High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. In: Bone Marrow Transplantation. 2006 ; Vol. 37, No. 10. pp. 929-935.
@article{8e1dffdbb398469c95e74cf195c5c7c1,
title = "High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy",
abstract = "The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. Their disease had been refractory (defined as less than partial response) to one (18 patients) or two (24 patients) regimens of neoadjuvant chemotherapy. Twenty-nine patients had surgery before HDCT. The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. Thirty patients had complete remission, eight had a PR, one had a minor response, and three had progressive disease. In seven of 13 patients whose disease was inoperable before HDCT, it became operable. After a median follow-up of 42 months, 21 patients were alive, and 15 remained disease free. Five-year overall survival (OS) was 57{\%} (CI, 50-64{\%}), and the estimated 5-year progression-free survival was 40{\%} (CI, 32-48{\%}). Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable. A randomized study is warranted in this patient population.",
keywords = "Autologous transplantation, Breast neoplasm, High-dose chemotherapy, Preoperative chemotherapy, Resistant",
author = "Ueno, {N. T.} and S. Konoplev and Buchholz, {T. A.} and T. Smith and G. Rond{\'o}n and P. Anderlini and Giralt, {S. A.} and Gajewski, {J. L.} and Donato, {M. L.} and M. Cristofanilli and Champlin, {R. E.}",
year = "2006",
month = "5",
doi = "10.1038/sj.bmt.1705355",
language = "English (US)",
volume = "37",
pages = "929--935",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy

AU - Ueno, N. T.

AU - Konoplev, S.

AU - Buchholz, T. A.

AU - Smith, T.

AU - Rondón, G.

AU - Anderlini, P.

AU - Giralt, S. A.

AU - Gajewski, J. L.

AU - Donato, M. L.

AU - Cristofanilli, M.

AU - Champlin, R. E.

PY - 2006/5

Y1 - 2006/5

N2 - The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. Their disease had been refractory (defined as less than partial response) to one (18 patients) or two (24 patients) regimens of neoadjuvant chemotherapy. Twenty-nine patients had surgery before HDCT. The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. Thirty patients had complete remission, eight had a PR, one had a minor response, and three had progressive disease. In seven of 13 patients whose disease was inoperable before HDCT, it became operable. After a median follow-up of 42 months, 21 patients were alive, and 15 remained disease free. Five-year overall survival (OS) was 57% (CI, 50-64%), and the estimated 5-year progression-free survival was 40% (CI, 32-48%). Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable. A randomized study is warranted in this patient population.

AB - The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. Their disease had been refractory (defined as less than partial response) to one (18 patients) or two (24 patients) regimens of neoadjuvant chemotherapy. Twenty-nine patients had surgery before HDCT. The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. Thirty patients had complete remission, eight had a PR, one had a minor response, and three had progressive disease. In seven of 13 patients whose disease was inoperable before HDCT, it became operable. After a median follow-up of 42 months, 21 patients were alive, and 15 remained disease free. Five-year overall survival (OS) was 57% (CI, 50-64%), and the estimated 5-year progression-free survival was 40% (CI, 32-48%). Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable. A randomized study is warranted in this patient population.

KW - Autologous transplantation

KW - Breast neoplasm

KW - High-dose chemotherapy

KW - Preoperative chemotherapy

KW - Resistant

UR - http://www.scopus.com/inward/record.url?scp=33646922289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646922289&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705355

DO - 10.1038/sj.bmt.1705355

M3 - Article

VL - 37

SP - 929

EP - 935

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -